WallStSmart

Bicycle Therapeutics Ltd (BCYC)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Bicycle Therapeutics Ltd generates 8457% more annual revenue ($63.50M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. BCYC earns a higher WallStSmart Score of 33/100 (F).

BCYC

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 3/9Altman Z: 1.70

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BCYC2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BCYC4 concerns · Avg: 3.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

Market CapQuality
$300.19M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BCYC

The strongest argument for BCYC centers on Price/Book, Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BCYC

The primary concerns for BCYC are EPS Growth, Altman Z-Score, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BCYC carries more volatility with a beta of 1.56 — expect wider price swings.

BCYC is growing revenue faster at -91.1% — sustainability is the question.

BCYC generates stronger free cash flow (-67M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BCYC scores higher overall (33/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bicycle Therapeutics Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?